YPL114W Antibody

How can I validate the specificity of my antibody against my target protein?

The gold standard for antibody validation involves using genetic controls, specifically comparing wild-type and knockout cell lines. According to data from YCharOS, a collaborative initiative characterizing antibodies against the human proteome, the optimal testing methodology involves:

• Using an appropriately selected wild-type cell

• Creating an isogenic CRISPR knockout version of the same cell

• Performing side-by-side comparisons in multiple applications

This approach provides rigorous and broadly applicable results across different experimental techniques . For Western blot applications, a well-performing antibody will show bands only in the wild-type lane and not in the knockout lysate. For secreted proteins, centrifuged cell culture media is used instead of cell lysates .

What are the relative performance rates of different antibody types across common laboratory applications?

Recent comprehensive characterization of 614 commercial antibodies by YCharOS revealed significant differences in performance between antibody types:

The data clearly demonstrates that recombinant antibodies significantly outperform both polyclonal and monoclonal antibodies across all three common laboratory applications . This performance difference should be considered when selecting antibodies for experimental procedures.

Is success in one antibody application predictive of performance in other applications?

While intuition might suggest that antibody performance would be consistent across applications, the data indicates otherwise. Analysis of antibody performance across applications shows that success in immunofluorescence (IF) is actually the best predictor of performance in Western blot (WB) and immunoprecipitation (IP) .

What approaches can be utilized to design multi-specific antibodies that target multiple epitopes simultaneously?

Multi-specific antibodies can be engineered using several established methods as demonstrated in HIV-1 research. One effective approach is the DVD-Ig format (dual-variable-domain immunoglobulin), where:

• Two scFvs are cloned in frame with sequences encoding connecting G4S linkers

• These are attached to both the N and C termini of a full IgG1 antibody

• Heavy and light chain engineering is performed in parallel

For example, researchers created trispecific antibodies targeting HIV-1 by fusing variable domains of heavy chains (iMab and PRO140) with a GGGGSGGGGS linker, followed by a constant region (CH1-CH2-CH3). Then, an ScFv from either 10E8, PGDM1400, or PGT121 was connected to the C terminus of CH3 via a GGGGSGGGGS linker .

This trispecific design allows a single molecule to interact with three independent targets: (1) the host receptor CD4, (2) the host co-receptor CCR5, and (3) distinct domains in the envelope glycoprotein of HIV-1. ELISA, HIV-1 pseudovirus neutralization assays, and in vivo experiments demonstrated that these trispecific antibodies exhibited higher potency and breadth than any previously described single bnAb .

How do the structural domains of antibodies contribute to their function and engineering potential?

Antibodies consist of three functional components: two Fragment antigen binding domains (Fabs) and the fragment crystallizable (Fc), with the Fabs linked to the Fc by a hinge region that allows conformational flexibility. Each domain's structure contributes uniquely to function:

• Variable domains (VH and VL): Form the antigen-binding site, with each domain contributing three complementarity-determining regions (CDRs)

  • CDR loops are positioned in proximity to each other due to the packing of β-sheets

  • Both sequence and length variations in CDRs contribute to diversity

  • CDR-H3 shows the most variability and often undergoes conformational changes upon antigen binding

• Constant domains: Provide structural stability and effector functions

  • Composed of the immunoglobulin fold with two tightly packed anti-parallel β-sheets

  • One β-sheet has four β-strands (↓A ↑B ↓E ↑D) and the other has three (↓C ↑F ↓G)

  • Covalently linked by an intra-domain disulfide bridge between two cysteines

• Elbow angle: The orientation between V domains and C domains

  • Can vary significantly (116° to 226° for kappa light chains, wider range for lambda)

  • Involves a molecular ball-and-socket joint that can restrict angles to 180°

Understanding these structural elements is crucial for antibody engineering, including humanization, affinity modulation, stability enhancement, and the development of bispecific and multispecific molecules .

What factors influence the VH-VL pairing in antibody engineering, and how does this affect function?

When engineering antibodies, particularly during humanization, VH-VL pairing considerations are critical for both stability and function:

• Stability considerations: Selected germlines should form a stable Fv complex

• Orientation preservation: The mutual orientation of VH and VL domains should correspond to that in the parental antibody

The importance of maintaining VH-VL orientation was demonstrated in a study of anti-lysozyme murine antibody HyHEL-10. After humanization, affinity dropped 10-fold despite all antigen-antibody interactions being conserved. The issue was traced to changed relative orientation of VH and VL. A single back mutation (W47Y) completely recovered the affinity, confirming the critical nature of domain orientation .

Regarding promiscuity of VH-VL pairing, analysis of over 800 different antibodies against 28 clinically relevant antigens showed that while a given VH sequence can pair with many light chain sequences of both λ and κ types, certain pairings like VH1-λVL1 are preferentially enriched, representing 25% of the antigen-specific selected repertoire .

What are the advantages and limitations of using yeast systems for antibody expression?

Yeast expression systems, particularly Pichia pastoris, offer several advantages for antibody production:

• Scalable production: Can achieve expression levels of 10 mg/L in flask culture with 1% methanol induction, with potential for higher yields in bioreactors

• Proper assembly: Heavy and light chains assemble correctly to form heterotetramers

• Signal peptide processing: N-terminal amino acid sequencing confirms proper processing of signal peptides

• N-glycosylation capability: Unlike bacterial systems, yeasts can perform N-glycosylation, though with different patterns than mammalian cells

• Glycan characteristics: Analysis reveals a mixture of Man9-GlcNAc2, Man10-GlcNAc2, Man11-GlcNAc2, and Man12-GlcNAc2, without hyper-mannosylated glycans

These advantages make yeast particularly suitable for applications where mammalian glycosylation isn't critical. Functional testing shows that antibodies produced in P. pastoris can have similar affinity curves and Kd values compared to the same antibodies produced in CHO cells, as demonstrated with an anti-human HER II antibody .

How can the yeast surface display technology be optimized for antibody selection and affinity maturation?

Yeast surface display has emerged as a powerful platform for antibody selection and affinity maturation, with specific methodological requirements:

• Library Construction:

  • Clone antibody gene libraries into specific yeast display vectors (e.g., pDNL6)

  • Transform into suitable yeast strains (e.g., EBY100)

  • Initial growth in SD/CAA media at 30°C until OD600 >2

  • Induce display in SG/R CAA media for 36-48 hrs at 20°C

• Selection Process:

  • Wash yeast with buffer (30mM Tris pH 8.0 with 0.5% BSA)

  • Incubate with biotinylated target antigens (typically 100nM) for 30-60 min

  • Detect binding with streptavidin-Alexa 633 and display with anti-SV5-PE

  • Use fluorescence-activated cell sorting (FACS) to isolate cells showing both binding and display

• Affinity Measurements:

  • Measure binding at different antigen concentrations at equilibrium

  • Calculate estimated KD by determining concentration at half-maximal binding

  • Use nonlinear regression analysis for binding curve fitting

This method is particularly advantageous when combined with phage display for initial selection, providing greater control over selection conditions and enabling high-throughput screening of large antibody libraries .

What approaches can improve the production of antibody fusion proteins while maintaining functionality?

Creating functional antibody fusion proteins presents unique challenges. A high-throughput method using yeast display can directly select antibodies most suitable for conversion to chimeric formats:

• Fusion Protein Design Strategy:

  • Convert selected scFv libraries to fluorescent chimeric form by cloning thermal green protein (TGP) into the linker between VH and VL

  • Use CPEC (Circular Polymerase Extension Cloning) assembly with TGP-specific primers

  • Transform into appropriate cells for expression

• Simultaneous Selection for Multiple Properties:

  • Use flow cytometry to simultaneously assess binding (target recognition) and functionality (fluorescence)

  • This approach identifies antibodies that maintain both binding specificity and functional expression in the fusion format

• Expression Benefits:

  • Conversion to scTGP (single-chain TGP) format improved protein production 3-12 fold compared to conventional scFv

  • Enabled one-step immunofluorescence assays without additional detection reagents

This methodology is particularly valuable as it addresses a key challenge: antibodies selected solely on binding specificity are not necessarily ideal candidates for creating fusion proteins with additional functionalities like fluorescence, toxicity, or enzymatic activity .

How can active learning strategies improve the efficiency of antibody-antigen binding prediction?

Active learning approaches can significantly enhance antibody-antigen binding prediction, particularly in library-on-library settings where many antigens are screened against many antibodies:

• Methodology:

  • Start with a small labeled subset of antibody-antigen pairs

  • Use machine learning models to predict interactions

  • Strategically select which additional data points to experimentally validate

  • Iteratively expand the labeled dataset based on model uncertainty or predicted informative value

• Performance Improvements:

  • Top-performing active learning algorithms reduced the number of required antigen mutant variants by up to 35%

  • Accelerated the learning process by 28 steps compared to random baseline selection

  • Particularly valuable for out-of-distribution prediction scenarios (when test antibodies/antigens are not represented in training data)

This approach is especially relevant for experimental antibody research where generating comprehensive binding data is costly and time-consuming. By intelligently selecting which experiments to perform, researchers can obtain more informative data with fewer experiments .

What role can AI play in designing novel antibody sequences against specific antigens?

AI approaches, particularly protein Large Language Models (LLMs), are emerging as powerful tools for generating novel antibody sequences with specific binding properties:

• MAGE (Monoclonal Antibody GEnerator) represents a significant advancement:

  • Fine-tuned protein LLM for generating paired variable heavy and light chain antibody sequences

  • Requires only an antigen sequence as input, without needing a pre-existing antibody template

  • Generates diverse antibody sequences distinct from training datasets

• Experimental Validation:

  • AI-generated antibodies showed experimentally validated binding specificity against:

    • SARS-CoV-2 receptor-binding domain (RBD)

    • Emerging avian influenza H5N1 viral hemagglutinin

    • Respiratory syncytial virus A prefusion F protein

This technology has the potential to revolutionize rapid antibody design against emerging pathogens, significantly enhancing drug discovery efforts by reducing the time and resources needed for initial antibody screening .

How might therapeutic monoclonal antibodies impact endogenous antibody production in patients?

Research on Ebola virus disease survivors provides insight into the potential impacts of therapeutic monoclonal antibodies on endogenous antibody responses:

• Clinical Observations:

  • Almost a quarter (24%) of Ebola survivors were seronegative upon discharge from treatment centers

  • Antibody concentrations decreased rapidly over time in follow-up studies

  • The probability of remaining seropositive for at least two antigens after 36 months varied significantly depending on the treatment received:

    • 53.6% for participants who received ansuvimab

    • 73.5% for participants who received REGN-EB3

    • 76.8% for participants who received remdesivir

    • 78.5% for participants who received ZMapp

• Implications:

  • Monoclonal antibody treatments might negatively affect the production of endogenous antibodies

  • This could potentially increase the risk of reinfection or reactivation of disease

  • Different monoclonal antibody treatments appear to have varying effects on the development of endogenous immunity

These findings highlight important considerations for therapeutic antibody development and administration strategies, particularly for infectious diseases where long-term immunity is desirable.

What factors should be considered when designing kinetics experiments for bivalent antibody-antigen interactions?

Kinetic analysis of bivalent antibody-antigen interactions presents unique challenges that require specialized experimental design:

• Methodological Approach:

  • Surface plasmon resonance (SPR) is commonly used, but when antigens (rather than antibodies) are immobilized, a bivalent analyte (1:2) binding model is required

  • Standard experimental designs may result in non-identifiable parameters during non-linear optimization

  • A system of ordinary differential equations for analyzing 1:2 binding kinetics data provides more reliable results

• Key Optimization Strategies:

  • Implement grid search on parameter initialization

  • Use profile likelihood approach to determine parameter identifiability

  • Develop simulation-guided experimental designs to ensure reliable estimation of all rate constants

• Importance for Research:

  • Understanding binding kinetics provides guidance for optimizing pharmacology

  • Binding affinity may not be directly linked with therapeutic efficacy

  • Proper kinetic analysis expedites therapeutic antibody discovery

These considerations are particularly important in antibody discovery research, where accurate assessment of binding kinetics can significantly impact the selection of candidates for further development.

How can researchers access validated antibody characterization data to inform reagent selection?

Several resources now provide comprehensive antibody validation data that can guide researchers in selecting appropriate reagents:

• YCharOS Platform:

  • Consolidates data into reports (one protein per report) available on Zenodo (https://zenodo.org/communities/ycharos/)

  • Converting reports into F1000 articles, collected on the YCharOS Gateway and indexed via PubMed

  • Data accessible through searches on the Antibody Registry

  • For each protein target, includes Western blot, immunoprecipitation, and immunofluorescence data comparing wild-type and knockout samples

• Finding YCharOS Data:

  • The data can be searched in AntibodyRegistry.org and other portals (RRID.site, dkNet.org)

  • Search term 'ycharos' returns all characterized antibodies

  • Searching by target or catalogue number also retrieves YCharOS information

  • Green stars in the RRID.site portal and dkNet highlight YCharOS contributions

• International Bioimaging Networks:

  • Promoted through Canada BioImaging (CBI)

  • BioImaging North America (BINA)

  • Global BioImaging (GBI)

Accessing this validated data before selecting antibodies can save researchers significant time and resources by avoiding poorly performing reagents, particularly important given the variable quality of commercial antibodies.

What criteria should be used to evaluate vendor claims about antibody performance?

When evaluating vendor claims about antibody performance, researchers should consider:

By applying these criteria, researchers can make more informed decisions when selecting antibodies, potentially saving significant time and resources by avoiding antibodies unlikely to perform as claimed.